ArticleSensors (Basel, Switzerland)2025
Compact Quantum Cascade Laser-Based Noninvasive Glucose Sensor Upgraded with Direct Comb Data-Mining.
Article in Sensors (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Mid-infrared spectral analysis has long been recognized as the most accurate noninvasive blood glucose measurement method, yet no practical compact mid-infrared blood glucose sensor has ever passed the accuracy benchmark set by the USA Food and Drug Administration (FDA): to substitute for the finger-pricking glucometers in the market, a new sensor must first show that 95% of their glucose measurements have errors below 15% of these glucometers. Although recent innovative exploitations of the well-established Fourier-transform infrared (FTIR) spectroscopy have reached such FDA accuracy benchmarks, an FTIR spectrometer is too bulky. The advancements of quantum cascade lasers (QCLs) can lead to FTIR spectrometers of reduced size, but compact QCL-based noninvasive blood glucose sensors are not yet available. This work reports on two compact sensor system designs, both reaching the FDA accuracy benchmark. Each design commonly comprises a mid-infrared QCL for emission, a multiple attenuation total reflection prism (MATR) for data acquisition, and a computer-controlled infrared detector for data analysis. The first design translates the comb-like signals into conventional spectra, and then data-mines the resultant spectra to yield blood glucose concentrations. When a pressure actuator is employed to press the patient's hypothenar against the MATR, the sensor accuracy is considered to reach the FDA accuracy benchmark. The second design abandons the data processing step of translating combs-to-spectra and directly data-mines the "first-hand" comb signal. Beyond increasing the measurement accuracy to the FDA accuracy benchmark, even without a pressure actuator, direct comb data-mining upgrades the sensor system with speed and data integrity, which can impact the healthcare of diabetic patients. Specifically, the sensor performance is validated with 492 glucose absorption scans in the time domain, each with 20 million datapoints measured from four subjects with glucose concentrations of 3.9-7.9 mM. The sensor data-mines 164 sets of critical singularity strengths, each comprising 4 critical singularity strengths directly from the 9840 million raw signal datapoints, and the 656 critical singularity strengths are subjected to a machine-learning regression model analysis, which yields 164 glucose concentrations. These concentrations are correlated with those measured with a standard finger-pricking glucometer. An accuracy of 99.6% is confirmed from the 164 measurements with errors not more than 15% from the reference of the standard glucometer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.